Biomarkers as targets for CAR-T/NK cell therapy in AML

Biomarker Research

Review

Kailin Xu¹  Ruonan Shao²  Honglei Xin²  Suyu Jiang²  Jingan Liu²  Rong Huang²  Zijian Li²  Yilin Zhu²  Xiaofeng Shi² 

[1] Affiliated Hospital of Xuzhou Medical University, 221004, Xuzhou, Jiangsu, China;Second Affiliated Hospital of Nanjing Medical University, No.262, North Zhongshan Road, 210003, Nanjing, Jiangsu, China;

关键词: Acute myeloid leukemia;    AML;    CAR-T;    CAR-NK;    Target;    Treatment;    Research progress;   

DOI  :  10.1186/s40364-023-00501-9

 received in 2023-03-25, accepted in 2023-05-11,  发布年份 2023

来源: Springer

【 摘 要 】

The most common kind of acute leukemia in adults is acute myeloid leukemia (AML), which is often treated with induction chemotherapy regimens followed by consolidation or allogeneic hematopoietic stem cell transplantation (HSCT). However, some patients continue to develop relapsed or refractory AML (R/R-AML). Small molecular targeted drugs require long-time administration. Not all the patients hold molecular targets. Novel medicines are therefore needed to enhance treatment outcomes. T cells and natural killer (NK) cells engineered with chimeric antigen receptors (CARs) that target antigens associated with AML have recently been produced and are currently being tested in both pre-clinical and clinical settings. This review provides an overview of CAR-T/NK treatments for AML.

【 授权许可】

CC BY   
© The Author(s) 2023